• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

    2/15/24 8:59:58 PM ET
    $IVC
    Industrial Specialties
    Health Care
    Get the next $IVC alert in real time by email
    SC 13D/A 1 d761521dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Invacare Holdings Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    46124A101

    (CUSIP Number)

    Robin Shah

    Tenor Capital Management Company, L.P.

    810 Seventh Avenue, Suite 1905

    New York, NY 10019

    (212) 918-5300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 13, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

    CUSIP No. 46124A101

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Tenor Capital Management Company, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     12,010,302 (1)

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

      SHARED DISPOSITIVE POWER

     

     12,010,302 (1)

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,010,302 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     57.3% (2)

    14.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IA

     

    (1)

    Includes 10,957,247 shares of common stock, par value $0.001 per share (the “Common Stock”), of Invacare Holdings Corporation (the “Issuer”) that may be issued upon conversion of the 713,698 shares of the Issuer’s 9.00% Series A Convertible Participating Preferred Stock (the “Convertible Preferred Stock”) beneficially owned by the Reporting Person. As of December 15, 2023, the most recent quarterly dividend date, the Convertible Preferred Stock conversion ratio was adjusted to 15.3528:1 to reflect an accruing payment-in-kind dividend at 9.00% per annum.

    (2)

    Calculated based on 20,957,227 shares of Common Stock, which includes 10,957,247 shares of Common Stock issuable upon conversion of the Reporting Person’s holdings of Convertible Preferred Stock, plus 9,999,980 shares of Common Stock outstanding as of May 12, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2023.

     

     

    Page 2


    SCHEDULE 13D

    CUSIP No. 46124A101

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Tenor Opportunity Master Fund, Ltd.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     12,010,302 (1)

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

      SHARED DISPOSITIVE POWER

     

     12,010,302 (1)

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,010,302 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     57.3% (2)

    14.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    Includes 10,957,247 shares of Common Stock of the Issuer that may be issued upon conversion of the 713,698 shares of the Convertible Preferred Stock beneficially owned by the Reporting Person. As of December 15, 2023, the most recent quarterly dividend date, the Convertible Preferred Stock conversion ratio was adjusted to 15.3528:1 to reflect an accruing payment-in-kind dividend at 9.00% per annum.

    (2)

    Calculated based on 20,957,227 shares of Common Stock, which includes 10,957,247 shares of Common Stock issuable upon conversion of the Reporting Person’s holdings of Convertible Preferred Stock, plus 9,999,980 shares of Common Stock outstanding as of May 12, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2023.

     

    Page 3


    SCHEDULE 13D

    CUSIP No. 46124A101

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Robin Shah

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     12,010,302 (1)

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

      SHARED DISPOSITIVE POWER

     

     12,010,302 (1)

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,010,302 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     57.3% (2)

    14.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN, HC

     

    (1)

    Includes 10,957,247 shares of Common Stock of the Issuer that may be issued upon conversion of the 713,698 shares of the Convertible Preferred Stock beneficially owned by the Reporting Person. As of December 15, 2023, the most recent quarterly dividend date, the Convertible Preferred Stock conversion ratio was adjusted to 15.3528:1 to reflect an accruing payment-in-kind dividend at 9.00% per annum.

    (2)

    Calculated based on 20,957,227 shares of Common Stock, which includes 10,957,247 shares of Common Stock issuable upon conversion of the Reporting Person’s holdings of Convertible Preferred Stock, plus 9,999,980 shares of Common Stock outstanding as of May 12, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2023.

     

    Page 4


    Explanatory Note

    This Amendment No. 3 (this “Schedule 13D Amendment”) to the Schedule 13D filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2023, as amended by Amendment No. 1 on September 13, 2023 and Amendment No. 2 on February 2, 2024 (as amended by this Schedule 13D Amendment, the “Schedule 13D”), is being filed on behalf of Tenor Capital Management Company, L.P., a Delaware limited partnership (“Tenor Capital”), Tenor Opportunity Master Fund, Ltd., a Cayman Islands corporation (the “Master Fund”) and Robin Shah, a citizen of the United States of America (together with Tenor Capital and the Master Fund, the “Reporting Persons”), with respect to the common stock, par value $0.001 per share (the “Common Stock”), of Invacare Holdings Corporation, a Delaware corporation (the “Issuer”).

    Other than as set forth below, all Items in the Schedule 13D are materially unchanged. Capitalized terms used in this Schedule 13D Amendment which are not defined herein have the meanings given to them in the Schedule 13D.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented to include the following:

    On February 13, 2024, the Reporting Persons, together with the Named Stockholders, representing more than a majority of the voting power of the Issuer’s issued and outstanding capital stock, acted by written consent in lieu of a special meeting to, among other things, appoint Jame Donath, J. Carney Hawks and Samuel Brill as directors of the Issuer and remove Steven Rosen, Randel Owen and Peter Kuipers as directors of the Issuer. In addition, certain provisions of the Issuer’s bylaws were amended to provide the Issuer with greater flexibility relating to the calling of special meetings of directors and the compensation of directors.

    The foregoing is not intended to limit the matters previously disclosed in Item 4 of the Schedule 13D.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby amended and supplemented to include the following:

    The information set forth in Item 4 of this Schedule 13D Amendment is hereby incorporated by reference.

     

    Page 5


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 15, 2024

     

    TENOR CAPITAL MANAGEMENT COMPANY, L.P.
    By:  

    /s/ Robin Shah

    Name:   Robin Shah
    Title:   Managing Member of its general partner, Tenor Management GP, LLC
    TENOR OPPORTUNITY MASTER FUND, LTD.
    By:  

    /s/ Robin Shah

    Name:   Robin Shah
    Title:   Authorized Signatory

     

    ROBIN SHAH

    /s/ Robin Shah

     

    Page 6

    Get the next $IVC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVC

    DatePrice TargetRatingAnalyst
    10/29/2021$11.00 → $9.00Outperform
    Oppenheimer
    9/10/2021$17.00 → $8.00Buy
    Needham
    8/19/2021$11.00Outperform
    Oppenheimer
    More analyst ratings

    $IVC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Invacare with a new price target

      Oppenheimer reiterated coverage of Invacare with a rating of Outperform and set a new price target of $9.00 from $11.00 previously

      10/29/21 7:39:40 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Needham reiterated coverage on Invacare with a new price target

      Needham reiterated coverage of Invacare with a rating of Buy and set a new price target of $8.00 from $17.00 previously

      9/10/21 5:41:14 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Oppenheimer initiated coverage on Invacare with a new price target

      Oppenheimer initiated coverage of Invacare with a rating of Outperform and set a new price target of $11.00

      8/19/21 7:41:53 AM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Davidson Kempner Capital Management Lp claimed ownership of 717,650 shares (SEC Form 3)

      3 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      2/12/24 4:15:59 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Ferreira Cintia was granted 84,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:15:51 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Purtill Geoffrey was granted 1,204,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:13:41 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    SEC Filings

    See more
    • Invacare Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      2/16/24 5:16:23 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form NT 10-Q filed by Invacare Corporation

      NT 10-Q - INVACARE HOLDINGS Corp (0000742112) (Filer)

      11/15/23 4:06:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      9/13/23 4:31:43 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IVC
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Corporation Takes Action to Strengthen Its Financial Position and Drive Long-Term Growth Through Voluntary Prearranged Chapter 11 Cases That Do Not Include Its International Operations

      Refinancing action will reduce net debt by approximately 65% Global manufacturing and delivery of products to continue uninterrupted to meet robust customer demand Strong sequential improvement achieved in preliminary 4Q22 financial results Executed strategic actions accelerating a renewed focus on core businesses Invacare Corporation (NYSE:IVC) ("Invacare" or "the company"), a leading manufacturer and distributor of medical equipment used in non-acute care settings, today announced actions to strengthen the company and position it for long-term success. To facilitate its financial restructuring, the company has entered into a Restructuring Support Agreement (the "RSA" or "Agreement")

      2/1/23 8:33:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Additional Draw of Term Loans

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announced the consummation of an additional draw of $5,500,000 of term loans under to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC ("Highbridge"), as of December 23, 2022. Commenting on the financing, Geoff Purtill, president and chief executive officer stated, "As guided in the 3Q22 earnings release, Europe achieved sequential growth in revenues and profitability driven by improved supply chain circumstances giving us confidence that our transformation program is reaping benefits. Today's announcement provides us with greater flexibility as we execute against our stated strategy. We are p

      12/27/22 8:02:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Appoints Geoff Purtill President and Chief Executive Officer

      Invacare Corporation (NYSE:IVC) announced today that its Board of Directors has named Geoffrey P. Purtill as President and Chief Executive Officer, roles that he has served on an interim basis since August 28, 2022. Non-executive Chairman of the Board of Directors Michael J. Merriman, Jr, said, "On behalf of the Board, we are excited to elevate Geoff Purtill into the role of President and CEO. The Board determined that Geoff is the right steward of the company as it undergoes significant transformation and embarks on a new chapter. Geoff has proven adept at guiding our global businesses through change, both in his previous role overseeing the EMEA and APAC businesses, and now in his curren

      11/21/22 5:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Executive Leadership Changes

      Appoints Geoff Purtill as Interim Chief Executive Officer and Michael Merriman as Board Chairman Invacare Corporation (NYSE:IVC) today announced changes to its senior management team and Board of Directors to advance its previously announced business transformation initiatives, address supply chain challenges, and strengthen its financial performance. Geoffrey P. Purtill, who had been serving as the company's Senior Vice President and General Manager, EMEA and APAC, was named interim President and Chief Executive Officer, replacing Matthew E. Monaghan, who has left from his role as Chairman, President and Chief Executive Officer, effective August 28, 2022. The Board of Directors has comme

      8/29/22 7:35:00 AM ET
      $AM
      $IVC
      $NDSN
      $RGS
      Natural Gas Distribution
      Utilities
      Industrial Specialties
      Health Care

    $IVC
    Financials

    Live finance-specific insights

    See more
    • Invacare Reports Results for Third Quarter 2022

      Updates strategic priorities with the discontinuation of the production of respiratory products Anticipates sequential improvement in revenues and profitability in 4Q22 Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended September 30, 2022. Executive Summary Reflecting on the quarter and the company's progress against its transformation program, Geoffrey Purtill, interim president and chief executive officer, said "We remain committed to taking necessary and decisive action to increase shareholder value. After carefully evaluating our strategic options, we have determined that the lifestyle and mobility & seating categories are core

      11/7/22 4:15:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announces that it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Monday, November 7, 2022. The company will provide a live conference call and webcast to discuss these financial results on Tuesday, November 8, 2022, at 8:30 AM ET. Investors and other interested parties may access the webcast and conference call in the following ways: Those wishing to participate via webcast can register and access the event at https://events.q4inc.com/attendee/918973030 Those wishing to participate via telephone can dial 844-200-6205 (U.S. and Canada) or 929-526-1599 (internation

      10/20/22 8:00:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Reports Results for Second Quarter 2022

      Achieved sequential improvement in profitability and free cash flow Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended June 30, 2022. Executive Summary Reflecting on the quarter, Matt Monaghan, chairman, president, and chief executive officer, said "In 2Q22, we achieved sequential revenue growth of 4.7% in mobility & seating products driven by increased adoption of our compelling product portfolio. We continue to experience elevated backlog across all product categories and regions, and see strong demand in mobility & seating and lifestyle products. We are working diligently to increase output and convert order backlog into sales.

      8/8/22 4:20:00 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:49 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:18 PM ET
      $IVC
      Industrial Specialties
      Health Care